Publication of promising preclinical data on FG001s effect in treatment of cancer
Copenhagen, Denmark, 23 August 2021. FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce the first publication of preclinical data where the Company’s compound FG001 is used as a photothermal therapy agent for treatment of cancer. The new feature of FG001 complements the surgical targeting and opens new opportunities for the realization of clinical and commercial potential of the Company’s uPAR-targeting technology platform.Earlier this year the Company announced it had acquired worldwide exclusive rights to use FG001 for photothermal therapy. Now the first preclinical study